How Much Does Peptide Therapy Cost? Monthly Prices at ACT 2

None of the six peptide products listed above sermorelin in the table is FDA-approved for any use. BPC-157, TB-500, KPV, DSIP (emideltide), Epithalon and MOTS-c are prepared by a licensed compounding pharmacy on a prescription written for an individual patient. The FDA states plainly that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed.

The FDA has named all six in a safety context. Its page on bulk drug substances that may present significant safety risks lists BPC-157, TB-500, KPV, emideltide (DSIP), Epithalon and MOTS-c. For most of them it describes a possible risk of immune reactions for certain routes of administration and complexities with peptide-related impurities; for KPV it says it has identified no human exposure data by any route. That page, last updated in April 2026, lists all six as substances whose nominations for compounding were withdrawn.

The position is still moving. In July 2026 the FDA's Pharmacy Compounding Advisory Committee met to consider several of these substances for the list of bulk substances that pharmacies may compound under section 503A. Advisory committees make non-binding recommendations; adding a substance to that list requires formal rulemaking, which had not completed at the time of review. The BPC-157 regulatory status page and the DSIP regulatory status page set out the detail.

What that means for cost: you are paying for a clinician's judgment and a pharmacy's preparation, not for a product with an FDA-reviewed label. The price says nothing about what a peptide will or will not do.

Covered. The free assessment and clinician eligibility review cost nothing; you pay only if a clinician finds a peptide appropriate and you decide to go ahead. There is no membership fee. As with most ACT 2 treatments, the monthly price covers the clinical care and the medication dispensed by a licensed pharmacy, so there is no separate pharmacy bill.

Not covered. Lab work is priced separately. If a clinician orders a comprehensive panel before prescribing, it is $199. Shipping and taxes, where they apply, appear before checkout.

How the total builds. Because every peptide tier is monthly with no package, the arithmetic is linear. Three months of a single peptide is $975; three months of either blend is $1,050. Add $199 if one comprehensive panel is ordered. Those figures are arithmetic, not a recommended course: how long a peptide is prescribed, if at all, is decided at clinical review.

The welcome offer. New patients get 10% off their first order through the welcome page. It does not apply to lab panels.

ACT 2 does not bill insurance, Medicare or Medicare Advantage for any treatment or lab panel. With peptides there is a second problem: even if you submitted a claim yourself, there is little for a plan to recognize.

Insurance. Health plans and Medicare drug plans build coverage around FDA-approved drugs used for recognized indications. Medicare's own Part D manual states that bulk powders used for compounding do not meet the definition of a Part D drug and are not covered. A compounded peptide with no approved use gives a plan nothing to attach coverage to. Plan for these as fully out-of-pocket.

HSA and FSA. Whether a purchase qualifies depends on IRS rules and your plan administrator, not on the seller; IRS Publication 502 defines what counts as medical care. ACT 2 cannot declare any purchase eligible, and for an unapproved compounded peptide an administrator may ask for a letter of medical necessity or decline. Budget as if it will not be reimbursed. The pricing and insurance FAQ covers the general mechanics.

Sermorelin ODT is $199 a month. Unlike the other six, it is not on the FDA's list of bulk substances that may present significant safety risks, and it was once sold as an FDA-approved drug. It is still compounded today; the sermorelin cost page explains why it has no approved version to price against.